Loading...
Loading...
By Sofía Garduño - Mon, 08/18/2025 - 09:14
The US FDA approves Wegovy to treat adults with MASH and moderate to advanced liver fibrosis, excluding cirrhosis.
https://mexicobusiness.news/tag/wegovy
More Health
By Sofía Garduño - Mon, 02/24/2025 - 11:27
The FDA confirms that US supply of Wegovy and Ozempic now meets or exceeds demand, following Novo Nordisk's US$6.5 billion investment.
By Sofía Garduño - Tue, 02/18/2025 - 13:42
A new survey shows GLP-1 medication access is increasingly important for job retention and hiring, with demand driving employer-sponsored coverage.
By MBN Staff - Tue, 12/03/2024 - 10:37
Canada approves Novo Nordisk’s Wegovy to reduce heart attack risk in obese adults with cardiovascular disease.
By MBN Staff - Thu, 08/08/2024 - 17:41
Lilly and Novo Nordisk compete in the weight-loss market amid significant supply shortages. Analysts forecast a 50-50 market split by late 2024.
By MBN Staff - Thu, 07/11/2024 - 09:35
Only 25% of patients continue using Wegovy or Ozempic after two years, raising concerns about the cost-effectiveness of these expensive drugs.
By Anmol Motwani - Wed, 07/10/2024 - 09:51
Novo Nordisk’s semaglutide in Wegovy and Ozempic shows higher NAION risk. Prices are notably lower in Mexico compared to the US.
By MBN Staff - Wed, 06/26/2024 - 12:02
Novo Nordisk's US$4.1 billion investment in North Carolina will expand production of Wegovy and Ozempic, creating 1,000+ jobs.
By MBN Staff - Thu, 06/20/2024 - 10:26
Global obesity rates are driving demand for safe, effective weight-loss drugs, prompting heavy pharmaceutical R&D investment.
By MBN Staff - Mon, 06/03/2024 - 09:42
Novo Nordisk sues nine US medical spas, clinics, and pharmacies for selling non-FDA approved semaglutide products, which could have impurities.
